El-Bietar Javier, Bollard Catherine
Center for Cell and Gene Therapy , Baylor College of Medicine, Texas Children's Hospital, Houston, Texas 77030, USA.
Pediatr Hematol Oncol. 2011 Nov;28(8):627-39. doi: 10.3109/08880018.2011.628367.
Epstein-Barr virus (EBV)-associated lymphomas represent a broad spectrum of diseases and can be characterized by their pattern of viral latency. These pathologies display the importance of healthy T cell-mediated control of the EBV-infected B cells. Burkitt's lymphoma is the least immunogenic and has a type I latency pattern. Hodgkin's and a variety of non-Hodgkin's lymphomas exhibit antigens of type II latency. Posttransplant lymphoproliferative disease in the solid organ and hematopoietic stem cell transplant setting as well as lymphomas arising in primary immunodeficiency patients are tumors with type III latency. This last group expresses all 9 latent proteins and is the most immunogenic. T-cell approaches including donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes can be used to treat these diseases. The authors describe the biology of these EBV-associated lymphomas and review the methodology and outcomes of existing T cell-based therapies as well as strategies to improve their efficacy.
爱泼斯坦-巴尔病毒（EBV）相关淋巴瘤是一类广泛的疾病，可根据其病毒潜伏模式进行特征描述。这些病理情况显示了健康T细胞介导的对EBV感染B细胞的控制的重要性。伯基特淋巴瘤免疫原性最低，具有I型潜伏模式。霍奇金淋巴瘤和多种非霍奇金淋巴瘤表现出II型潜伏抗原。实体器官和造血干细胞移植环境中的移植后淋巴细胞增生性疾病以及原发性免疫缺陷患者中发生的淋巴瘤是具有III型潜伏的肿瘤。最后这一组表达所有9种潜伏蛋白，免疫原性最强。包括供体淋巴细胞输注和EBV特异性细胞毒性T淋巴细胞的过继转移在内的T细胞方法可用于治疗这些疾病。作者描述了这些EBV相关淋巴瘤的生物学特性，并综述了现有基于T细胞疗法的方法和结果以及提高其疗效的策略。
